| No information available. |
Summary of Clinical Use  |
| ARGX-110 is in clinical trials for various cancers; Max Phase 2. Click here to view ClinicalTrials.gov's list of registered ARGX-110 trials. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04241549 | A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment | Phase 1 Interventional | Janssen Pharmaceutical K.K. | ||
